Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of [89Zr]-Oxine-NCR100 in Knee Osteoarthritis
NCT07139431Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of NCR100 in knee osteoarthritis (OA), sponsored by Nuwacell Biotechnologies. Primary endpoint: Standardized Uptake Values (SUV) and %ID at Day 22. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
NCR100
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07139431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139431.